RenovoRx, Inc. (NASDAQ:RNXT) Q1 2026 Earnings Call Transcript
RenovoRx, Inc. (NASDAQ:RNXT) Q1 2026 Earnings Call Transcript May 14, 2026RenovoRx, Inc. reports earnings inline with expectations. Reported EPS is $-0.08 EPS, expectations were $-0.08.
Renovorx Inc. (RNXT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AIGH Investment Partners Orin Hirschman | 4,405,439 | $4,317,330 | +19% | 0.27% |
| 2. | Citadel Investment Group Ken Griffin | 133,597 | $130,925 | -43% | 0% |
| 3. | Renaissance Technologies Jim Simons | 11,400 | $11,172 | -13% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.79 | 25,000 | $19,690.00 | 142,380 | 2026-05-19 | Filing | |
| $0.00 | 9,720 | $0.00 | 9,720 | 2026-03-20 | Filing | |
| $0.00 | 24,300 | $0.00 | 313,357 | 2026-03-20 | Filing | |
| $0.00 | 97,200 | $0.00 | 97,200 | 2026-03-20 | Filing | |
| $1.00 | 10,000 | $9,975.00 | 798,460 | 2026-01-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,666,098 | $1,632,776 | 0.29% | |
| 2. | 1,443,742 | $1,414,867 | 0% | |
| 3. | 424,148 | $415,687 | 0% | |
| 4. | 252,525 | $247,475 | 0% | |
| 5. | 240,330 | $235,523 | 0% |
News See All
RenovoRx, Inc. (NASDAQ:RNXT) Q3 2025 Earnings Call Transcript
RenovoRx, Inc. (NASDAQ:RNXT) Q3 2025 Earnings Call Transcript November 13, 2025RenovoRx, Inc. beats earnings expectations. Reported EPS is $-0.07946, expectations were $-0.08.
RenovoRx, Inc. (NASDAQ:RNXT) Q2 2025 Earnings Call Transcript
RenovoRx, Inc. (NASDAQ:RNXT) Q2 2025 Earnings Call Transcript August 14, 2025RenovoRx, Inc. reports earnings inline with expectations. Reported EPS is $-0.08 EPS, expectations were $-0.08.
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results
On Thursday, Ascendiant analyst Edward Woo raised the price target on RenovoRx Inc. (NASDAQ:RNXT) to $11.50 from $11, while maintaining a Buy rating on the shares.
RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript
RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript May 15, 2025RenovoRx, Inc. reports earnings inline with expectations. Reported EPS is $-0.08 EPS, expectations were $-0.08.